MelissaAlsinaMD

Assistant Professor of Medicine, University S Fla College of Medicine

Overview of Dr. Alsina

Dr. Melissa Alsina is a hematologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from University of Puerto Rico School of Medicine and has been in practice 29 years. Dr. Alsina accepts several types of health insurance, listed below. She is one of 45 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Hematology. She has more than 100 publications and over 500 citings.

Office
12902 USF Magnolia Dr
CSB 7TH floor Room 7162
Tampa, FL 33612
Book by Phone+1(816) 656-3328

Fax+1 813-449-6713

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1992 - 1995
San Juan City HospitalFellowship, Hematology and Medical Oncology, 1991 - 1992
VA Caribbean Healthcare SystemResidency, Internal Medicine, 1988 - 1991
University of Puerto Rico School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 2000 - 2026
PR State Medical License 2010 - 2022
OK State Medical License 1996 - 2002
TX State Medical License 1996 - 2002
American Board of Internal Medicine Hematology

Clinical Trials

CI-994 in Treating Patients With Advanced Myeloma Start of enrollment: 1997 Aug 01
Completed
Phase 2
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma Start of enrollment: 2001 Jan 01
Completed
Phase 2
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) Start of enrollment: 2003 Jun 01
Terminated
Phase 3
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Start of enrollment: 2005 Jun 01
Completed
Phase 2
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma Start of enrollment: 2005 Aug 01
Terminated
Phase 1, Phase 2
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) Start of enrollment: 2008 Sep 01
Completed
Phase 1, Phase 2
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma Start of enrollment: 2009 Feb 01
Completed
Phase 2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Sep 23
Completed
Phase 1, Phase 2
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Start of enrollment: 2017 Jun 01
Withdrawn
Phase 1, Phase 2
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide Start of enrollment: 2018 Oct 04
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

120 citations
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
Martha Q. Lacy, Melissa Alsina, Rafael Fonseca, M. Luisa Paccagnella, Carrie Lynn Melvin
Journal of Clinical Oncology. 2008-07-01
13 citations
Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization.
Laura B Oswald, Xiaoyin Li, Rodrigo Carvajal, Aasha I Hoogland, Lisa M Gudenkauf
Cancers. 2022-05-31
40 citations
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
Kai Rejeski, Doris K Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi
Journal of Hematology & Oncology. 2023-07-31

Abstracts/Posters

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Melissa Alsina, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Melissa Alsina, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
Melissa Alsina, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Corre...
Melissa Alsina, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
Melissa Alsina, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Press Mentions

BCMA-Directed CAR-T Therapy Shows Clinical Activity in Multiple MyelomaDecember 7th, 2020
Ash 2020 – Efficacy and Deaths Mark the Car-T Multiple Myeloma RaceDecember 5th, 2020
Bluebird Bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 5th, 2020
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PowerSelect HMO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield CA Local Access Plus HMO
Blue Shield California HMO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Connecticare FlexPOS
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Health Net California Large Group PPO
Health Net HMO - Employer Group
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment